Form 4: Natera Co-Founder Sells Shares Under 10b5-1 Plan

Jonathan Sheena, Natera's Co-Founder and Director, sold 1,500 shares of common stock on January 23, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Sheena, Co-Founder and Director of Natera, Inc. (NTRA), sold a total of 1,500 shares of common stock.
• The sales occurred on January 23, 2026, at weighted average prices ranging from $242.232 to $245.62 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 7, 2024.
• Following these transactions, Jonathan Sheena directly owns 264,078 shares and indirectly holds 21,782 shares through Caraluna 1 Trust and 21,782 shares through Caraluna 2 Trust.
• The reporting person disclaims beneficial ownership over the securities held by the trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It's a planned liquidity event rather than a reaction to new information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to recent company performance or news.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the insider's direct stake in the company, which some investors might interpret as a slight reduction in conviction.

Industry Context

This Form 4 filing reports a routine insider stock sale for Natera, a company operating in the biotechnology and healthcare sector. Such planned sales are common for executives seeking to diversify personal holdings or manage liquidity, and do not inherently reflect on broader industry trends or Natera's competitive position.

Related Party Transactions

• Jonathan Sheena disclaims beneficial ownership over shares held by the Caraluna 1 Trust and Caraluna 2 Trust, which are indirectly owned by him for the benefit of their beneficiaries.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, though the 10b5-1 plan context suggests it's a planned event rather than a signal of declining confidence.
• The company's operational or strategic direction is not directly impacted by this personal transaction.

Key Dates

Recommendation

The insider sale is a planned event under a 10b5-1 plan, which typically does not signal a change in the insider's long-term view of the company. Without additional information on Natera's fundamentals or market conditions, this Form 4 alone does not warrant a change from a 'hold' position.

Keywords

Natera, NTRA, Jonathan Sheena, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Co-Founder, Biotechnology, Healthcare